SCHEMBL5707753

SCHEMBL5707753

O=C1/C(=C/c2ccc(O)cc2)Oc2cc(O)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 4/20 1.00
▸ MAOA P21397 3/20 1.00
▸ MAOB P27338 3/20 1.00
▸ MEN1 O00255 7/20 0.83
▸ KMT2A Q03164 7/20 0.83
▸ POLB P06746 2/20 0.83
▸ RAB9A P51151 2/20 0.83
▸ RECQL P46063 3/20 0.78
▸ STK17B O94768 2/20 0.78
▸ KDM4E B2RXH2 2/20 0.78
▸ NPC1 O15118 2/20 0.78
▸ GAA P10253 2/20 0.78
▸ MAPT P10636 2/20 0.78
▸ PSMD14 O00487 1/20 0.78
▸ AURKA O14965 1/20 0.78
▸ DAPK3 O43293 1/20 0.78
▸ JAK2 O60674 1/20 0.78
▸ ALPL P05186 1/20 0.78
▸ ALPI P09923 1/20 0.78
▸ ALPG P10696 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30214422 1.00 TYR (1.00) TYRMAOAMAOBMEN1KMT2A
SCHEMBL29435856 1.00 TYR (1.00) TYRMAOAMAOBMEN1KMT2A
SCHEMBL30214414 0.92 TYR (0.86) TYRMAOAMAOBMEN1KMT2A
SCHEMBL28949991 0.92 TYR (0.86) TYRMAOAMAOBMEN1KMT2A
SCHEMBL30214416 0.91 MAOB (0.83) TYRMAOAMAOBMEN1KMT2A
SCHEMBL30214402 0.91 MAOB (0.83) TYRMAOAMAOBMEN1KMT2A
6-Hydroxy-4'-Chloro Aurone SCHEMBL30214415 0.91 ELANE (0.88) TYRMAOAMAOBMEN1KMT2A
SCHEMBL19462969 0.91 MAOA (0.83) TYRMAOAMAOBMEN1KMT2A
SCHEMBL21046449 0.91 MEN1 (1.00) TYRMAOAMAOBMEN1KMT2A
6-Hydroxy-4'-Chloro Aurone SCHEMBL30214387 0.91 ELANE (0.88) TYRMAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060228313-A1 Method of cosmetic depigmentation care by applying at least one aurone COLETICA (FR) 2006-10-12 — — US claimed
EP-1709964-A2 A method of cosmetic depigmentation care by applying at least one aurone ENGELHARD LYON (FR) 2006-10-11 — — EP claimed
US-11254700-B2 GSK-3β inhibitors and use thereof in methods of treatment UNIVERSITY OF HAWAII (US) 2022-02-22 — — US disclosed
US-20200331948-A1 GSK-3ß INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT UNIVERSITY OF HAWAII (US) 2020-10-22 — — US disclosed
WO-2010110647-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES BIOTROPICS MALAYSIA BERHAD (MY) 2010-09-30 — — WO disclosed
US-20060228313-A1 Method of cosmetic depigmentation care by applying at least one aurone COLETICA (FR) 2006-10-12 — — US disclosed
EP-1709964-A2 A method of cosmetic depigmentation care by applying at least one aurone ENGELHARD LYON (FR) 2006-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331948-A1 GSK-3ß INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT GSK3B, GSK3A, GSKIP TYR 3102/4885MAOA 1977/4885MAOB 1651/4885
US-20060228313-A1 Method of cosmetic depigmentation care by applying at least one aurone TYR, MITF, MC1R TYR 1/4885MAOA 23/4885MAOB 27/4885
US-11254700-B2 GSK-3β inhibitors and use thereof in methods of treatment GSK3B, GSK3A, GSKIP TYR 2809/4885MAOA 2012/4885MAOB 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback